These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 15883258

  • 1. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL.
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [Abstract] [Full Text] [Related]

  • 2. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease.
    Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW.
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):63-8. PubMed ID: 11234910
    [Abstract] [Full Text] [Related]

  • 3. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 4. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
    Monsch AU, Giannakopoulos P, GAL-SUI Study Group.
    Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
    [Abstract] [Full Text] [Related]

  • 5. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression.
    Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, Spirling S, Schierz K, Winiecki P, Sorbi S, Herholz K.
    Biol Psychiatry; 2005 Feb 15; 57(4):412-21. PubMed ID: 15705358
    [Abstract] [Full Text] [Related]

  • 6. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R, Scheltens P, Barkhof F, Rombouts SA.
    Brain; 2006 Jan 15; 129(Pt 1):141-57. PubMed ID: 16251213
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.
    Kim YW, Kim DY, Shin JC, Park CI, Lee JD.
    Clin Neuropharmacol; 2009 Jan 15; 32(2):63-8. PubMed ID: 18978490
    [Abstract] [Full Text] [Related]

  • 10. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
    Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):104-10. PubMed ID: 19833161
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
    Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S.
    Dement Geriatr Cogn Disord; 2007 Feb 01; 23(6):401-5. PubMed ID: 17409748
    [Abstract] [Full Text] [Related]

  • 15. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group.
    Neurology; 2007 Jul 31; 69(5):448-58. PubMed ID: 17664404
    [Abstract] [Full Text] [Related]

  • 16. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D, Hutchinson M, Larsen JP.
    Int J Geriatr Psychiatry; 2003 Oct 31; 18(10):937-41. PubMed ID: 14533126
    [Abstract] [Full Text] [Related]

  • 17. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW, Lee JG, Lee BJ, Kim YH.
    Int Clin Psychopharmacol; 2007 Mar 31; 22(2):63-8. PubMed ID: 17293705
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.